~ Buy the SYNRIBO (omacetaxine mepesuccinate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR SYNRIBO

All Clinical Trials for SYNRIBO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00375219 ↗	Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation	Completed	Cephalon	Phase 2	2006-09-01	To evaluate the safety and efficacy of subcutaneous administration of omacetaxine mepesuccinate (HHT) in achieving a clinical response in CML patients in chronic, accelerated, or blast phase who have failed prior imatinib therapy and have the T315I kinase domain gene mutation.
NCT00375219 ↗	Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation	Completed	ChemGenex Pharmaceuticals	Phase 2	2006-09-01	To evaluate the safety and efficacy of subcutaneous administration of omacetaxine mepesuccinate (HHT) in achieving a clinical response in CML patients in chronic, accelerated, or blast phase who have failed prior imatinib therapy and have the T315I kinase domain gene mutation.
NCT00375219 ↗	Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation	Completed	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 2	2006-09-01	To evaluate the safety and efficacy of subcutaneous administration of omacetaxine mepesuccinate (HHT) in achieving a clinical response in CML patients in chronic, accelerated, or blast phase who have failed prior imatinib therapy and have the T315I kinase domain gene mutation.
NCT00375219 ↗	Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation	Completed	Teva Branded Pharmaceutical Products, R&D Inc.	Phase 2	2006-09-01	To evaluate the safety and efficacy of subcutaneous administration of omacetaxine mepesuccinate (HHT) in achieving a clinical response in CML patients in chronic, accelerated, or blast phase who have failed prior imatinib therapy and have the T315I kinase domain gene mutation.
NCT00462943 ↗	Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML	Completed	Cephalon	Phase 2	2007-03-01	A Phase II open-label trial of subcutaneous HHT (omacetaxine mepesuccinate) in the treatment of patients who are resistant to or intolerant to Tyrosine Kinase Inhibitors.
NCT00462943 ↗	Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML	Completed	ChemGenex Pharmaceuticals	Phase 2	2007-03-01	A Phase II open-label trial of subcutaneous HHT (omacetaxine mepesuccinate) in the treatment of patients who are resistant to or intolerant to Tyrosine Kinase Inhibitors.

Clinical Trial Conditions for SYNRIBO

Condition Name

Condition Name for SYNRIBO
Intervention	Trials
Chronic Myeloid Leukemia	2
Leukemia	2
Refractory Acute Myeloid Leukemia	1
Refractory Myelodysplastic Syndrome	1

Condition MeSH

Condition MeSH for SYNRIBO
Intervention	Trials
Leukemia, Myeloid	5
Preleukemia	4
Myelodysplastic Syndromes	4
Leukemia	4

Clinical Trial Locations for SYNRIBO

Trials by Country

Trials by Country for SYNRIBO
Location	Trials
United States	21
Canada	2
Hungary	2
Poland	2
Germany	2

Trials by US State

Trials by US State for SYNRIBO
Location	Trials
Texas	5
Indiana	2
Georgia	2
Florida	2
California	2

Clinical Trial Progress for SYNRIBO

Clinical Trial Phase

Clinical Trial Phase for SYNRIBO
Clinical Trial Phase	Trials
Phase 2	4
Phase 1/Phase 2	2
Phase 1	1

Clinical Trial Status

Clinical Trial Status for SYNRIBO
Clinical Trial Phase	Trials
Completed	3
Terminated	2
Withdrawn	1

Clinical Trial Sponsors for SYNRIBO

Sponsor Name

Sponsor Name for SYNRIBO
Sponsor	Trials
Teva Pharmaceuticals USA	3
M.D. Anderson Cancer Center	3
Teva Branded Pharmaceutical Products, R&D Inc.	2

Sponsor Type

Sponsor Type for SYNRIBO
Sponsor	Trials
Industry	12
Other	5